

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Kazuo SUGAMURA et al.
Serial No. : To be assigned
Filed : Herewith
For : NON-HUMAN MAMMAL MODEL OF
AUTOIMMUNE DISEASE HAVING OX40L
GENE TRANSFERRED THEREINTO

745 Fifth Avenue,
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV 385417019 US

Date of Deposit: March 26, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Saddam Ahmed

(Typed or printed name of person mailing paper or fee)

S. Ahmed

(Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is directed to the enclosed copies of the publications which were cited in the International Search Report of International Application No. PCT/JP02/07674. Also enclosed is a copy of Form PTO-1449 and the International Search Report.

As this Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits, it is believed that no fee is required for entry of this paper. However, the Commissioner is hereby authorized to charge any such fee, or credit any overpayment to Deposit Account 50-0320.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.


Applicants respectfully request that the Examiner considers and make of record the documents cited herewith and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Entry of this Information Disclosure Statement and an early examination on the merits are respectfully solicited.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By:



Thomas J. Kowalski

Reg. No. 32,147

Tel. No. (212) 588-0800

Fax. No. (212) 588-0500

Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO. 671302-2007		SERIAL NO. To be assigned	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT Kazuo SUGAMURA et al.			
				FILING DATE Herewith		GROUP To Be Assigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AB						
	AC						
	AD						
	AE						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AF		Ndhlovu, L. et al., "Critical Involvement of OX40 Ligand Signals in the T cell Priming Events During Experimental Autoimmune Encephalomyelitis," <u>The Journal of Immunology</u> , 167: 2991-99, 2001				
	AG		Ndhlovu, L. et al., "OX40 Ligand Signals are Critical for the T cell Priming Events During Experimental Autoimmune Encephalomyelitis," <u>FASEB J.</u> , 15(4): A344, 2001				
	AH		Higgins, L. et al., "Regulation of T Cell Activation In Vitro and In Vivo by Targeting the OX40-OX40 Ligand Interaction: Amelioration of Ongoing Inflammatory Bowel Disease with an OX40-IgG Fusion Protein, but not with an OX40 Ligand-IgG Fusion Protein," <u>The Journal of Immunology</u> , 162: 486-93, 1999				
	AI		Murata, K. et al., "Impairment of Antigen-presenting Cell Function in Mice Lacking Expression of OX40 Ligand," <u>J. Exp. Med.</u> , 191(2): 365-74, 2000				
	AJ						
	AK						
	AL						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							